ALGS - Aligos Therapeutics secures Euro1.8M grant to advance hepatitis B research

Aligos Therapeutics' (ALGS) Belgian subsidiary Aligos Belgium BV has been awarded a €1.8M grant by the Flemish Agency for Innovation and Entrepreneurship ((VLAIO)) to support a nonclinical research project related to combination therapy for Hepatitis B at Aligos (CoHeBA). The support will allow the company to collaborate with some of the esteemed leaders in the hepatitis B field to identify how its chronic hepatitis B ((CHB)) assets target components of the hepatitis B virus life cycle.Developing a greater understanding of the candidates’ mechanism of action will empower Aligos' scientific team to develop pharmacologically promising combination therapies and next-generation therapeutics. The project will be for a period of three years.

For further details see:

Aligos Therapeutics secures €1.8M grant to advance hepatitis B research